Substantial progresses have been achieved in the treatment of APL since introduction of the use of ATRA in the middle of eighty and ATO from *** CR rate was raised from 30％-40％ (1973-85) to 93％-100％ and the 5-year...
Substantial progresses have been achieved in the treatment of APL since introduction of the use of ATRA in the middle of eighty and ATO from *** CR rate was raised from 30％-40％ (1973-85) to 93％-100％ and the 5-year survival rate from 10％-45％ to more than 90％ (up to 2015).10-year DFS attaining 87％ in 199 getting CR APL patients was reported recently in a paper from our *** remain to be solved are: early death, resistance to the treatment and relapse and why the treatment can't be reproduced in others types of acute leukemia and cancer.
Objective: Poor graft function (PGF), including primary PGF and secondary PGF, is a serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).We recently reported that the abnormali...
Objective: Poor graft function (PGF), including primary PGF and secondary PGF, is a serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).We recently reported that the abnormalities of the BM microenvironment may contribute to the occurrence of secondary PGF ***, it remains uncertain whether the impaired BM microenvironment are involved in the pathogenesis of primary PGF.
Objective Bortezomib (btz) is the major and potent agent in multiple myeloma (MM) treatment and intravenous (IV) injection is its standard administration ***, peripheral neuropathy (PN) always limited the use of *** (...
Objective Bortezomib (btz) is the major and potent agent in multiple myeloma (MM) treatment and intravenous (IV) injection is its standard administration ***, peripheral neuropathy (PN) always limited the use of *** (SC) administration is an important alternative with comparable efficacy but better safety *** primary outcome of our previous study showed that SC administration of btz significantly decreased and delayed the development of PN in patients with newly diagnosed MM (NDMM) and relapse/refractory MM (RRMM).Here, we amplified the cohorts and extended follow up to further confirm our previous primary outcome in patients with NDMM.
暂无评论